LGT Group Foundation Sells 3,579 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

LGT Group Foundation decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 87,397 shares of the medical equipment provider’s stock after selling 3,579 shares during the period. LGT Group Foundation’s holdings in Intuitive Surgical were worth $29,574,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in ISRG. WCM Investment Management LLC bought a new stake in Intuitive Surgical in the fourth quarter valued at $575,536,000. International Assets Investment Management LLC boosted its holdings in Intuitive Surgical by 32,360.5% in the fourth quarter. International Assets Investment Management LLC now owns 686,865 shares of the medical equipment provider’s stock valued at $231,721,000 after acquiring an additional 684,749 shares in the last quarter. Alphinity Investment Management Pty Ltd boosted its holdings in Intuitive Surgical by 113.2% in the fourth quarter. Alphinity Investment Management Pty Ltd now owns 1,276,158 shares of the medical equipment provider’s stock valued at $430,525,000 after acquiring an additional 677,455 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Intuitive Surgical in the third quarter valued at $178,667,000. Finally, Quadrature Capital Ltd boosted its holdings in Intuitive Surgical by 466.2% in the third quarter. Quadrature Capital Ltd now owns 340,644 shares of the medical equipment provider’s stock valued at $99,601,000 after acquiring an additional 280,480 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Insider Activity

In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of the stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $375.39, for a total value of $141,146.64. Following the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at $2,067,272.73. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Robert Desantis sold 376 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $375.39, for a total transaction of $141,146.64. Following the completion of the sale, the executive vice president now directly owns 5,507 shares in the company, valued at $2,067,272.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total transaction of $78,400.00. Following the sale, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at $736,800. The disclosure for this sale can be found here. Insiders have sold 226,928 shares of company stock valued at $87,833,828 in the last ninety days. 0.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Raymond James lifted their price target on shares of Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a report on Thursday, January 25th. BTIG Research boosted their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research note on Friday, April 19th. Piper Sandler upped their price objective on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a report on Friday, April 19th. Jefferies Financial Group lifted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Finally, Citigroup upped their price target on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $396.17.

Intuitive Surgical Stock Up 0.2 %

ISRG traded up $0.63 during midday trading on Thursday, hitting $372.33. 245,871 shares of the company traded hands, compared to its average volume of 1,619,555. The company’s 50-day moving average is $385.79 and its 200 day moving average is $348.35. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $403.76. The firm has a market capitalization of $132.07 billion, a PE ratio of 67.09, a price-to-earnings-growth ratio of 4.79 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the prior year, the firm earned $1.00 earnings per share. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.